The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: IL-1 receptor antagonist (IL-1Ra) is a naturally occurring IL-1RI-binding molecule that blocks the biologic effects of the proinflammatory cytokine IL-1. A recombinant form of human IL-1Ra, anakinra (Kineret), has been approved for use in rheumatology initially to manage rheumatoid arthritis (RA) patients that are refractory to more conventional forms of treatment. OBJECTIVE: This review summarizes the experience with anakinra in the treatment of patients with rheumatic diseases emphasizing its beneficial effects in novel applications. METHODS: English-language trials of anakinra were searched using MEDLINE and abstracts from rheumatology scientific meetings. RESULTS/CONCLUSIONS: In the treatment of patients with RA anakinra is effective but inferior to TNF-alpha blocking agents. Over the last few years it has become increasingly evident that anakinra is highly effective and safe in patients with systemic-onset juvenile idiopathic arthritis, adult-onset Still's disease, hereditary autoinflammatory syndromes, Schnitzler's syndrome and recently in gouty attacks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122 · cited 1×
“Four years later this molecule, IL-1Ra, was purified and cloned [4] and a human recombinant analog was produced in Escherichia coli [5] .”
BackgroundINTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
A pilot study of IL-1 inhibition by anakinra in acute gout
So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727 · cited 2×
“Recently, a pilot study enrolling 10 patients with acute gout reported on the rapid clinical response to short-term daily administration of anakinra injections [16] .”
BackgroundCohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638 · cited 2×
“In humans anakinra was initially used in sepsis with very limited, unremarkable success [9] ; in patients with RA anakinra has proven effectiveness [10] .”
Background
Cited by
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Caspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
“Minimal 6 ( 17 ) 2 (13) 2 (12) 4 (27) 5 (31) 4 (27) 5 (31) 9 (29)”
A Review of the Microbial Production of Bioactive Natural Products and Biologics
Pham, J. V., Yilma, M. A., Feliz, A., Majid, M. T., Maffetone, N., Walker, J. R., Kim, E., Cho, H. J., Reynolds, J. M., Song, M. C., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01404 · Cited by 565
Bondeson, J., Blom, A. B., Wainwright, S., Hughes, C., Caterson, B., & van den Berg, W. B. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27290 · Cited by 419
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
Menu, P., & Vince, J. E. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04440.x · Cited by 389
The Inflammasomes in Kidney Disease
Anders, H.-J., & Muruve, D. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080798 · Cited by 351
Molecular mechanisms involved in inflammasome activation
Bryant, C., & Fitzgerald, K. A. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.06.002 · Cited by 347
Kanner, A. M., Schachter, S. C., Barry, J. J., Hersdorffer, D. C., Mula, M., Trimble, M., Hermann, B., Ettinger, A. E., Dunn, D., Caplan, R., et al. (2012) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2012.01.007 · Cited by 295
Role of the NLRP3 inflammasome in autoimmune diseases
Li, Z., Guo, J., & Bi, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110542 · Cited by 261
van de Veerdonk, F. L., Smeekens, S. P., Joosten, L. A. B., Kullberg, B. J., Dinarello, C. A., van der Meer, J. W. M., & Netea, M. G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914795107 · Cited by 248
“T is much recent interest in the processing and release of bioactive IL-1β, especially since the discovery that blockade of IL-1 receptors with the IL-1 receptor antagonist (IL-1Ra) is a very effective treatment for autoinflammatory disorders, such as familial Mediterranean fever (1), familial cold autoinflammatory sy…”
Background
Metadata
- Authors
- Kalliolias, G. D., & C Liossis, S.-N.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-03
- Volume
- 17
- Issue
- 3
- Pages
- 349-359
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2070900512
- Cited by
- 102
- References
- 6
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.